Skip to main content

Host-Tumor_Interactions_Research_Program News

Clamping Down the Metabolic Pipeline to B Cells

New research shows the nutritive needs of B cells are more flexible than previously thought, which could enable researchers to steer antibody production in the lymph nodes and spleen to better combat autoimmunity. Patients with high-risk diseases of the immune system, particularly systemic lupus erythematosus, could stand to benefit from the research findings. The study led by Mark Boothby, MD, and published in the Journal of Immunology, provides details regarding how murine B cells use different sugars as they mature into antibody-producing cells


Wednesday, February 28th, 2024
Waddell Walker Hancock Cancer Discovery Fund names first scholars

A research endeavor that seeks to develop a new cancer immunotherapy utilizing nanobody delivery and targeted heating of tumors has received funding from the Waddell Walker Hancock Cancer Discovery Fund. John Wilson, PhD, and Jeffrey Rathmell, PhD, aim to create a novel therapeutic that will reprogram regulatory T cells, which typically suppress immune responses, into killer T cells with antitumor activity. The key to this reprogramming is the STING signaling pathway, and the force needed to unlock it is fever-relevant temperature — a hypothesis based on recent discoveries from the group on how fevers affect immune responses.


Friday, February 16th, 2024
Gut microbiota metabolite protects against obesity: study
Vanderbilt researchers have discovered that beneficial bacteria in the small intestines produce a compound that protects against obesity.
Friday, December 8th, 2023
Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.


Friday, November 17th, 2023
Tumor antigens key to improving cancer immunotherapy: study Tumor antigens key to improving cancer immunotherapy study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.


Friday, November 17th, 2023
Crowe, Osheroff honored by AAMC Crowe Osheroff honored by AAMC

Vanderbilts James E. Crowe Jr MD and Neil Osheroff PhD are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event.


Monday, October 30th, 2023
Vanderbilt-led team receives 2023 Endeavor Award from The Mark Foundation for Cancer Research

A multidisciplinary team of investigators has received a 2023 Endeavor Award from The Mark Foundation for Cancer Research to support four closely linked projects exploring the fundamental mechanisms that drive the obesity-cancer connection, taking advantage of a rich collection of matched tumor and adipose tissue samples from patients.


Tuesday, October 24th, 2023
Unexpected Consequences of Rac1 Protein

Research provides insight into how these key proteins support kidney ducts' cellular integrity.


Wednesday, September 20th, 2023
James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center's James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.


Wednesday, September 13th, 2023
Study finds hallmarks of T cell exhaustion within hours of tumor exposure
Vanderbilt researchers found that T cells become exhausted within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.
Wednesday, August 23rd, 2023
Crowe’s research honored

Vanderbilt's James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization's annual awards program in Washington, D.C.


Thursday, March 23rd, 2023
Study reveals new strategy for reducing tumor growth, metastasis Study reveals new strategy for reducing tumor growth, metastasis
A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.
Thursday, December 17th, 2020
V Scholar Award to support Byndloss’ cancer research V Scholar Award to support Byndloss’ cancer research
Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award from the V Foundation for Cancer Research.
Wednesday, November 18th, 2020
New therapeutic target for lung cancer New therapeutic target for lung cancer
Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.
Thursday, November 12th, 2020
Ann Richmond Richmond receives legacy award from Society for Leukocyte Biology
Ann Richmond, PhD, Ingram Professor of Cancer Research, is the 2019 recipient of the Society for Leukocyte Biology Legacy Award.
Friday, December 13th, 2019
Charles Manning Project seeks new way to assess immunotherapy effectiveness
GE Healthcare has awarded researchers $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.
Thursday, November 7th, 2019
Jeffrey Rathmell Rathmell lands award from Lupus Research Alliance
Jeffrey Rathmell, PhD, is a 2019 recipient of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity.
Thursday, October 31st, 2019
Pietenpol, Wilson land Komen cancer research support Pietenpol, Wilson land Komen cancer research support
Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.
Thursday, October 24th, 2019
melanoma on forehead Potential second-line melanoma treatment identified
A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Friday, August 30th, 2019
fibroblast and collagen New window on fibrosis
A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.
Friday, August 9th, 2019
Jeffrey Rathmell Center for Immunobiology grows, bolsters program
The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.
Friday, July 19th, 2019
Gore, King elected to 2019 IAMBE Class of Fellows Gore, King elected to 2019 IAMBE Class of Fellows
John Gore, PhD, director of the Vanderbilt University Institute of Imaging Science (VUIIS), and Michael King, PhD, J. Lawrence Wilson Professor and chair of the Department of Biomedical Engineering at Vanderbilt University, were recently elected to the International Academy of Medical and Biological Engineering (IAMBE) 2019 Class of Fellows in recognition of their contributions in the field of medical and biological engineering.
Thursday, May 30th, 2019
virus illustration RNA processing and antiviral immunity
A recent study in Nature Communications defines the in vivo substrates of RIG-I like receptors (RLRs) during an oncogenic virus infection and reveals a relationship between cellular RNA processing and an innate antiviral immune response.
Friday, December 14th, 2018
VICC investigators in spotlight at AACR conference VICC investigators in spotlight at AACR conference
A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M.
Thursday, May 19th, 2016